Status:
COMPLETED
Packaging PrEP to Prevent HIV Among WWID
Lead Sponsor:
Drexel University
Conditions:
HIV/AIDS
Eligibility:
FEMALE
18+ years
Brief Summary
Evidence suggests women who inject drugs (WWID) are disproportionately vulnerable to HIV. If HIV incidence continues unchecked, 1 in 23 WWID in the United States will acquire HIV. This observational s...
Detailed Description
This prospective mixed methods study will be initiated within the largest SEP in the mid-Atlantic region. Over six months, we will use semi-structured and in-depth interviews based on the Behavioral M...
Eligibility Criteria
Inclusion
- HIV sero-negative
- Females
- Age ≥18 years
- Reporting non-prescription injection drug use and any of the following:
- Syringe sharing
- Injecting drugs with a HIV-positive partner
- Recent opioid agonist treatment but still injecting drugs
- Sex exchange
- Inconsistent condom use
- Recent bacterial sexually transmitted infection (STI)
- and/or sex with a HIV-positive partner
Exclusion
- HIV seropositivity
- Currently taking PrEP
- Pregnant, breastfeeding or trying to become pregnant
- Previous enrollment in the study
Key Trial Info
Start Date :
April 3 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 8 2019
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT03304912
Start Date
April 3 2018
End Date
October 8 2019
Last Update
July 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Drexel University Dornsife School of Public Health
Philadelphia, Pennsylvania, United States, 19104